Amit Khot

2.9k total citations
53 papers, 971 citations indexed

About

Amit Khot is a scholar working on Pathology and Forensic Medicine, Oncology and Hematology. According to data from OpenAlex, Amit Khot has authored 53 papers receiving a total of 971 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pathology and Forensic Medicine, 22 papers in Oncology and 21 papers in Hematology. Recurrent topics in Amit Khot's work include Lymphoma Diagnosis and Treatment (20 papers), Multiple Myeloma Research and Treatments (15 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Amit Khot is often cited by papers focused on Lymphoma Diagnosis and Treatment (20 papers), Multiple Myeloma Research and Treatments (15 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Amit Khot collaborates with scholars based in Australia, United States and United Kingdom. Amit Khot's co-authors include H. Miles Prince, Michael Dickinson, Constantine S. Tam, Simon J. Harrison, David Ritchie, Kate Burbury, David Westerman, Grant A. McArthur, Nadine Hein and Ross D. Hannan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Amit Khot

45 papers receiving 961 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amit Khot Australia 12 416 340 299 253 253 53 971
Michal Bar‐Natan United States 15 524 1.3× 149 0.4× 312 1.0× 364 1.4× 719 2.8× 41 1.3k
Paulo Lúcio Portugal 13 255 0.6× 163 0.5× 160 0.5× 181 0.7× 469 1.9× 30 854
Radovan Vrḫovac Croatia 15 223 0.5× 227 0.7× 253 0.8× 330 1.3× 243 1.0× 65 810
Poul Knoblauch Denmark 11 736 1.8× 401 1.2× 523 1.7× 72 0.3× 76 0.3× 17 1.3k
Sheeja T. Pullarkat United States 13 234 0.6× 272 0.8× 508 1.7× 113 0.4× 116 0.5× 43 980
Junjiro Tsuchiyama Japan 14 252 0.6× 218 0.6× 271 0.9× 76 0.3× 96 0.4× 30 674
L. Austin Doyle United States 12 338 0.8× 247 0.7× 407 1.4× 148 0.6× 85 0.3× 35 922
José García‐Laraña Spain 16 397 1.0× 274 0.8× 459 1.5× 118 0.5× 560 2.2× 39 932
Kerstin Allen United States 13 261 0.6× 472 1.4× 198 0.7× 467 1.8× 116 0.5× 18 754

Countries citing papers authored by Amit Khot

Since Specialization
Citations

This map shows the geographic impact of Amit Khot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amit Khot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amit Khot more than expected).

Fields of papers citing papers by Amit Khot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amit Khot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amit Khot. The network helps show where Amit Khot may publish in the future.

Co-authorship network of co-authors of Amit Khot

This figure shows the co-authorship network connecting the top 25 collaborators of Amit Khot. A scholar is included among the top collaborators of Amit Khot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amit Khot. Amit Khot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Handunnetti, Sasanka M., Amit Khot, Piers Blombery, et al.. (2025). Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma. Blood Advances. 10(5). 1733–1742.
2.
3.
Herling, Marco, Claire Dearden, Francesco Zaja, et al.. (2024). Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood Advances. 8(4). 842–845. 2 indexed citations
4.
5.
Maclachlan, Kylee, Jian Kang, Andrew Cuddihy, et al.. (2024). Targeting the ribosome to treat multiple myeloma. SHILAP Revista de lepidopterología. 32(1). 200771–200771. 6 indexed citations
6.
Lew, Thomas E., Edward R. Scheffer Cliff, Michael Dickinson, et al.. (2023). Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease. Leukemia & lymphoma. 64(11). 1792–1800. 5 indexed citations
7.
Lew, Thomas E., Adrian Minson, Michael Dickinson, et al.. (2023). Treatment approaches for patients with TP53-mutated mantle cell lymphoma. The Lancet Haematology. 10(2). e142–e154. 17 indexed citations
8.
9.
Francis, Jill, Lara Edbrooke, Jenelle Loeliger, et al.. (2021). Impact of an allied health prehabilitation service for haematologic patients receiving high-dose chemotherapy in a large cancer centre. Supportive Care in Cancer. 30(2). 1841–1852. 8 indexed citations
10.
Weyden, Carrie van der, et al.. (2021). Advances in Frontline Management of Peripheral T-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 21(6). 368–378. 1 indexed citations
11.
Thompson, Ella R., Tamia Nguyen, Paul Yeh, et al.. (2020). Clonal independence of <i>JAK2</i> and <i>CALR</i> or <i>MPL</i> mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing. Haematologica. 106(1). 313–315. 14 indexed citations
12.
Khot, Amit, Natalie Brajanovski, Donald P. Cameron, et al.. (2019). First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. Cancer Discovery. 9(8). 1036–1049. 132 indexed citations
13.
Handunnetti, Sasanka M., Amit Khot, Mary Ann Anderson, et al.. (2019). Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study. Blood. 134(Supplement_1). 3999–3999. 6 indexed citations
14.
Khot, Amit, Natalie Brajanovski, Donald P. Cameron, et al.. (2017). RNA Polymerase 1 Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Malignancies: Results of a Phase I First in Human Study. Blood. 130. 3835–3835. 2 indexed citations
15.
Quin, Jaclyn, Keefe T. Chan, Jennifer R. Devlin, et al.. (2016). Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. Oncotarget. 7(31). 49800–49818. 79 indexed citations
16.
Horton, Linda W., Loïc Ysebaert, M Levade, et al.. (2014). Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 29(4). 783–787. 169 indexed citations
17.
Khot, Amit, Christopher McCormack, Stephen Lade, et al.. (2014). Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood. 125(1). 71–81. 153 indexed citations
18.
Khot, Amit, Michael Dickinson, & H. Miles Prince. (2013). Romidepsin for peripheral T-cell lymphoma. Expert Review of Hematology. 6(4). 351–359. 8 indexed citations
19.
Khot, Amit, Michael Dickinson, Simon J. Harrison, et al.. (2012). A Risk-Adapted Protocol for Delayed Administration of Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation. Clinical Lymphoma Myeloma & Leukemia. 13(1). 42–47. 1 indexed citations
20.
Li, Jane, Amit Khot, & Kate Burbury. (2012). Acute Kidney Injury Requiring Dialysis following Carmustine and Etoposide during Autologous Stem Cell Transplantation. Chemotherapy. 58(5). 349–351. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michal Bar‐Natan Breakdown of academic impact, for papers by Paulo Lúcio Breakdown of academic impact, for papers by Radovan Vrḫovac Breakdown of academic impact, for papers by Poul Knoblauch Breakdown of academic impact, for papers by Sheeja T. Pullarkat Breakdown of academic impact, for papers by Junjiro Tsuchiyama Breakdown of academic impact, for papers by L. Austin Doyle Breakdown of academic impact, for papers by José García‐Laraña Breakdown of academic impact, for papers by Kerstin Allen
Rankless by CCL
2026